VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

BCG expressing MSP
Vaccine Information
  • Vaccine Name: BCG expressing MSP
  • Target Pathogen: Mycobacterium tuberculosis
  • Target Disease: Tuberculosis
  • Vaccine Ontology ID: VO_0004107
  • Type: Live, attenuated vaccine
  • Antigen: MSP, a 30-kDa major secretory protein or mycolyltransferase, is used as vaccine antigen (Horwitz et al., 2000).
  • Preparation: Recombinant BCG (rBCG30) was prepared using E.coli/mycobacteria shuttle plasmid pSMT3. Plasmid was electoporated into the wild-type M. bovis BCG Tice strain. The 30-kDa MSP was isolated from the subcultured strains and further processed prior to inclusion in the vaccine (Horwitz et al., 2000).
Host Response

Guinea pig Response

  • Host Strain: Hartley, 250-350g outbred male
  • Challenge Protocol: Animals were challenged nine weeks after first injection or skin testing via aerosol with 10-ml single-cell suspension containing 1x105 CFU (1st & 2nd experiment) or 2x105 CFU (3rd experiment) of M. tuberculosis Erdman, providing ~40 to 80 liver bacilli to lungs, respectively (Horwitz et al., 2000).
  • Efficacy: The highly susceptible guinea pig model of pulmonary TB, a model noteworthy for its close resemblance to human TB, was used for testing. Animals immunized with the recombinant BCG vaccine and challenged by aerosol with a highly virulent strain of M. tb. had 0.5 log fewer M. tb. bacilli in their lungs and 1 log fewer bacilli in their spleens on average than animals immunized with their parental conventional BCG vaccine counterparts. Statistically, the difference was highly significant. At necropsy, animals immunized with the recombinant BCG vaccine had fewer and smaller lesions in the lung, spleen, and liver and significantly less lung pathology than animals immunized with the parental BCG vaccine (Horwitz et al., 2000).
References
Horwitz et al., 2000: Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proceedings of the National Academy of Sciences of the United States of America. 2000 Dec 5; 97(25); 13853-8. [PubMed: 11095745].